Jakob Michael Riedl

7PUBLICATIONS
47CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 09, 2026
Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.

Qingxiang Lin, Alvin A Morales-Giron, Conrad Sander

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Dec 23, 2023
Incidence of Diabetes Mellitus and Its Impact on Outcomes in Patients Undergoing Surgical Pancreatectomy for Non-Malignant and Malignant Pancreatobiliary Diseases-A Retrospective Analysis.

Anna Schranz, Christoph Sternad, Faisal Aziz

|Dec 14, 2023
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.

Dominik A Barth, Florian Moik, Sarah Steinlechner

|Aug 23, 2020
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.

Jakob M Riedl, Dominik A Barth, Wolfgang M Brueckl

|Jul 09, 2020
The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer.

Michael Stotz, Dominik A Barth, Jakob M Riedl

Pageof 2

Frequent Collaborators

3 joint publications

Dominik Andreas Barth

3 joint publications

Peter Kornprat

3 joint publications

Martin Pichler

2 joint publications

Jacquelyn M Curtis